| Author | Mello, Francisco Campello do Amaral | |
| Author | Fernandes, Carlos Augusto | |
| Author | Gomes, Selma de Andrade | |
| Access date | 2017-05-11T14:08:54Z | |
| Available date | 2017-05-11T14:08:54Z | |
| Document date | 2012 | |
| Citation | MELLO, Francisco Campello do Amaral; FERNANDES, Carlos Augusto; GOMES, Selma de Andrade. Antiviral therapy against chronic hepatitis B in Brazil: high rates of lamivudine resistance mutations and correlation with HBV genotypes. Mem Inst Oswaldo Cruz, v.107, n.3, p.317-325, May 2012. | pt_BR |
| ISSN | 0074-0276 | pt_BR |
| URI | https://www.arca.fiocruz.br/handle/icict/18817 | |
| Language | eng | pt_BR |
| Publisher | Fundação Oswaldo Cruz. Instituto Oswaldo Cruz | pt_BR |
| Rights | open access | |
| Subject in Portuguese | Vírus da Hepatite B | pt_BR |
| Subject in Portuguese | Terapia | pt_BR |
| Subject in Portuguese | Lamivudina | pt_BR |
| Subject in Portuguese | Resistência a medicamentos antivirais | pt_BR |
| Title | Antiviral therapy against chronic hepatitis B in Brazil: high rates of lamivudine resistance mutations and correlation with HBV genotypes | pt_BR |
| Type | Article | |
| Abstract | The effectiveness of antiviral treatments of chronic hepatitis B has been poorly studied in Brazil. Here, hepatitis B virus (HBV) DNA positivity, drug resistance mutations and their association with HBV genotypes were evaluated in chronically HBV-infected patients under different drug regimens in Brazil. The study involved 129 patients under interferon or nucleos(t)ide analogue therapy for a median treatment time of 12 months. One hundred and five (81%) of these patients were treated with lamivudine (LAM), either in monotherapy or in combination with newer drugs, such as entecavir (ETV) or tenofovir (TDF). High (37.5-100%) rates of HBV DNA positivity were observed with all but one drug regimen (LAM + ETV). However, patients that were treated with ETV alone, TDF alone or with LAM combination therapies had a mean viral load that was 3-4 log lower than patients treated with LAM monotherapy. Of the patients treated with LAM, 47% developed resistance mutations. HBV genotypes A (59.1%), D (30.3%) and F (9.1%) were found. There was no association between the presence of LAM resistance mutations and genotypes, HBeAg status or treatment duration. Nevertheless, the rtM204V mutation was observed more frequently (12/13, 92%) in genotype A than in the others (p = 0.023). Six out of nine isolates that contained the rtM204I mutation belonged to genotype D and half of them displayed a single mutation. Genotype D isolates with the rtM204V variant preferentially displayed a triple mutation, while genotype A preferentially displayed a double mutation (p = 0.04). | pt_BR |
| Affilliation | Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Virologia Molecularl. Rio de Janeiro, RJ. Brasil. | pt_BR |
| Affilliation | Laboratório Central de Saúde Pública Noel Nutels. Rio de Janeiro, RJ, Brasil. | pt_BR |
| Affilliation | Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Virologia Molecularl. Rio de Janeiro, RJ. Brasil. | pt_BR |
| Subject | HBV | pt_BR |
| Subject | Therapy | pt_BR |
| Subject | lamivudine | pt_BR |
| Subject | antiviral drug resistance | pt_BR |
| e-ISSN | 1678-8060 | |
| xmlui.metadata.dc.subject.ods | 03 Saúde e Bem-Estar | |
